Concord Biotech
Concord Biotech Ltd, a leading biopharmaceutical company headquartered in India, has established itself as a key player in the global biotechnology industry since its inception in 2000. With a strong focus on the development and manufacturing of biopharmaceuticals, the company operates primarily in India and has expanded its reach to various international markets. Specialising in the production of biosimilars and active pharmaceutical ingredients (APIs), Concord Biotech is renowned for its commitment to quality and innovation. The company’s core products include a range of biosimilars that cater to therapeutic areas such as oncology and autoimmune diseases, setting them apart through rigorous research and development processes. Recognised for its significant contributions to the biopharmaceutical sector, Concord Biotech has achieved notable milestones, including successful product launches and strategic partnerships, solidifying its position as a trusted name in the industry.
DitchCarbon Score
How does Concord Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Concord Biotech's score of 10 is lower than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Concord Biotech's reported carbon emissions
In 2023, Concord Biotech, headquartered in India, reported total carbon emissions of approximately 15,740,760 kg CO2e, comprising 14,340,180 kg CO2e from Scope 1 and 42,409,680 kg CO2e from Scope 2 emissions. The company did not report any Scope 3 emissions for that year. This represents a slight increase in emissions compared to 2022, when total emissions were approximately 14,046,480 kg CO2e, with 13,460,580 kg CO2e from Scope 1 and 39,507,900 kg CO2e from Scope 2. For 2024, Concord Biotech has not disclosed specific emissions data but continues to report emission intensity metrics. The total Scope 1 and Scope 2 emission intensity in terms of physical output was reported as approximately 23,640,000 kg CO2e in 2023, and approximately 23,980,000 kg CO2e in 2022. Currently, Concord Biotech has not set any specific reduction targets or climate pledges, nor does it inherit emissions data from a parent company. The company is actively monitoring its emissions and has disclosed its performance metrics, but further commitments or initiatives to reduce carbon emissions have not been outlined.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Concord Biotech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
